Valuing a fertility clinic requires calculating EBITDA (not SDE like service businesses). EBITDA = Earnings Before Interest, Taxes, Depreciation, Amortization. Start with your last three years of tax returns and current YTD P&L. EBITDA is net income (before taxes) plus: interest expense (if financed), taxes (add back), depreciation (non-cash expense from equipment, buildout), and amortization (intangible assets). For example: if your clinic shows $800K net income, $0 interest (no debt), $200K depreciation (ultrasound machines, incubators, lab equipment), and $50K amortization (goodwill or intangible assets), EBITDA = $800K + $200K + $50K = $1.05M. This $1.05M is your earnings anchor for multiple determination.

Now assess your six drivers against buyer expectations:

**Cycle Volume Assessment.** Pull your records from last 3 years: calculate annual IVF cycle count (fresh cycles + frozen embryo transfer cycles). Calculate cycle growth rate year-over-year. 400+ cycles annually = strong volume (commands 14x-20x EBITDA multiples); 250-400 cycles = mid-range (12x-15x); below 250 = challenged (10x-12x or below). Calculate average revenue per cycle: total annual revenue ÷ annual cycles = revenue per cycle (target $12K-$16K with ancillary services, $10K-$13K fresh-only). Plot your cycle flow by quarter: is it seasonal (summer/fall peaks, winter/spring valleys) or year-round stable? Stable cycle flow throughout year is preferred by buyers because it improves clinic utilization and cash flow predictability.

**Success Rate Validation.** Request your SART-reported data from your lab director or compliance officer: live birth rate per cycle, by patient age groups (20-34, 35-37, 38-40, 41+), for the most recent complete data year. Compare your rates against SART national averages: if your clinic is at 45% LBR for patients 20-34, you're in top quartile; 40-42% is median/competitive; below 38% is below-average. Success rate disadvantage directly impacts patient acquisition cost (weaker outcomes = higher marketing spend) and patient retention (patients leave for higher-success clinics). Document your blastocyst quality score (percent of embryos reaching blastocyst on day 5/6, which correlates with live birth), fertilization rate (normal fertilization/mature oocytes), and embryo grading quality. Buyers also assess: do you perform PGT-A (preimplantation genetic testing)? If yes, PGT-A utilization rate (percent of cycles using PGT) indicates advanced capability and patient population sophistication.

**Physician Staffing & Dependency.** List all REI physicians: names, FTE status (full-time, part-time, consulting), years with your clinic, case load (estimated cycles per physician annually), salary/compensation structure. Calculate percent of total cases performed by top physician: if founder REI performs 70%+ of retrievals and transfers, you have high owner-dependency. Buyers discount 30-40% for single-physician dependency or require earn-out structures dependent on physician retention (e.g., 25% of purchase price paid over 3 years conditional on physician staying). If you have 2 full-time REIs each performing 40-50% of cases, dependency is balanced and buyer risk is lower. Also document: do you have contingency plan if REI departs (recruiting network, partner agreements with other clinics)? Can your other physicians absorb departing physician's cases without compromising success rates?

**Lab Accreditation & Technology.** Confirm your lab certifications: CLIA-certified (required), CAP-accredited (preferred), state-specific lab licenses. Document your embryology team: number of embryologists, years of experience, training credentials. Document your equipment: what generation are your incubators (closed-system incubators with EmbryoScope time-lapse capability are preferred), are you using media systems optimized for embryo development, do you have vitrification equipment for egg/embryo freezing? Advanced technology (EmbryoScope time-lapse imaging, vitrification capability, PGT-A lab partnership) adds buyer confidence in success rate sustainability. Weak lab infrastructure (outdated incubators, no vitrification, limited embryology staffing) triggers buyer concern about success rate sustainability.

**Ancillary Service Revenue Breakdown.** Categorize your revenue by service type: fresh IVF cycles (% of revenue, average revenue per cycle), frozen embryo transfer cycles (% of revenue, average revenue), egg freezing cycles (% of revenue, average revenue), donor egg programs (% of revenue, revenue per cycle), surrogacy services (% of revenue, revenue per case). Calculate ancillary services as % of total revenue: ideally 25-40% of revenue comes from ancillary services beyond fresh IVF. If ancillary is <10%, you're missing revenue optimization opportunity. If ancillary is 35%+, you've diversified revenue and improved clinic efficiency (frozen cycles and egg freezing use infrastructure without fresh retrieval complexity). Buyers see ancillary diversification as: (1) upsell opportunity (cross-sell frozen cycles, egg freezing to existing patient base), (2) margin opportunity (frozen cycles have 20-30% higher margins than fresh cycles), (3) risk mitigation (if fresh cycle demand weakens, other services provide revenue stability).

**Payer & Insurance Relationships.** Document your payer mix: what percent of cases are covered by employer fertility benefits (Progyny, Carrot, employer direct plans)? What percent are out-of-pocket patients? What percent are covered by traditional insurance (health plans with fertility coverage)? Ideally 30-40% of revenue comes from networked employer benefit programs because these patients are predictable, non-price-sensitive, and managed by benefit coordinator. Out-of-pocket patients (60-70% of cases) are price-sensitive, require significant marketing investment, and have lower retention. Buyers assess: are you in-network with major fertility benefit platforms? Do you have direct relationships with major regional employers? Can you expand payer relationships post-acquisition? Document your patient acquisition channels: percent of new patients from employer referrals (ideal 30%+), physician referrals (20-30%), Google/web search (20-30%), social media/reputation (10-20%). If you're heavily dependent on web/Google acquisition, buyer sees high customer acquisition cost and retention risk.

Putting valuation together: Your baseline is 10x EBITDA. If your cycle volume is 450 cycles annually and growing 12% year-over-year, add 0.5x (cycle score: 10.5x). If success rates are 46% LBR for patients under 35 (above SART median), add 0.5x (success score: 11.0x). If you have 2 full-time REIs with balanced case distribution and 1 part-time consultant, add 2.0x (physician score: 13.0x). If your lab is CAP-accredited with vitrification, PGT-A capability, and experienced embryology team, add 1.0x (lab score: 14.0x). If ancillary services are 32% of revenue (egg freezing, donor, surrogacy), add 1.0x (ancillary score: 15.0x). If 35% of cases come from Progyny and employer benefit networks, add 2.0x (payer score: 17.0x). You're now at 17x EBITDA—a premium fertility clinic valuation. Single-physician clinics with weak payer relationships and ancillary services would start at 10x and potentially reach only 10x-12x EBITDA.